Relevance of interferon regulatory factor-8 expression in myeloid-tumor interactions

Journal of Interferon and Cytokine Research

Volumn 36, Issue 7, 2016, Pages 442-453

  Abrams, Scott I ^a   Netherby, Colleen S ^a   Twum, Danielle Y F ^a   Messmer, Michelle N ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR;

ADAPTIVE IMMUNITY; ARTICLE; BONE MARROW CELL; BONE MARROW TUMOR; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; DENDRITIC CELL; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; MONOCYTE; MYELOID PROGENITOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; ANIMAL; CELL COMMUNICATION; DISEASE EXACERBATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; MYELOID-DERIVED SUPPRESSOR CELL; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CELL COMMUNICATION; CELL DIFFERENTIATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOMODULATION; INTERFERON REGULATORY FACTORS; MYELOID CELLS; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84978131751     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2015.0174     Document Type: Article

References (121)

1. Aliper AM, Frieden-Korovkina VP, Buzdin A, Roumiantsev SA, Zhavoronkov A. 2014. A role for G-CSF and GM-CSF in nonmyeloid cancers. Cancer Med 3(4):737-746.
2. Auffray C, Sieweke MH, Geissmann F. 2009. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 27:669-692.
3. Becker AM, Michael DG, Satpathy AT, Sciammas R, Singh H, Bhattacharya D. 2012. IRF-8 extinguishes neutrophil production and promotes dendritic cell lineage commitment in both myeloid and lymphoid mouse progenitors. Blood 119(9): 2003-2012.
4. Bill MA, Nicholas C, Mace TA, Etter JP, Li C, Schwartz EB, Fuchs JR, Young GS, Lin L, Lin J, He L, Phelps M, Li PK, Lesinski GB. 2012. Structurally modified curcumin analogs inhibit STAT3 phosphorylation and promote apoptosis of human renal cell carcinoma and melanoma cell lines. PLoS One 7(8):e40724.
5. Bornstein C, Winter D, Barnett-Itzhaki Z, David E, Kadri S, Garber M, Amit I. 2014. A negative feedback loop of transcription factors specifies alternative dendritic cell chromatin States. Mol Cell 56(6):749-762.
6. Burchert A, Cai D, Hofbauer LC, Samuelsson MK, Slater EP, Duyster J, Ritter M, Hochhaus A, Muller R, Eilers M, Schmidt M, Neubauer A. 2004. Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ ABL and down-regulates bcl-2. Blood 103(9):3480-3489.
7. Chakraborty A, Guha S. 2007. Granulocyte colony-stimulating factor/granulocyte colony-stimulating factor receptor biological axis promotes survival and growth of bladder cancer cells. Urology 69(6):1210-1215.
8. Condamine T, Gabrilovich DI. 2011. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 32(1):19-25.
9. Condamine T, Mastio J, Gabrilovich DI. 2015. Transcriptional regulation of myeloid-derived suppressor cells. J Leukoc Biol 98(6):913-922.
10. Crook KR, Liu P. 2014. Role of myeloid-derived suppressor cells in autoimmune disease. World J Immunol 4(1):26-33.
11. Damuzzo V, Pinton L, Desantis G, Solito S, Marigo I, Bronte V, Mandruzzato S. 2015. Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin Cytom 88(2):77-91.
12. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. 2009. Increased circulating myeloidderived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58(1):49-59.
13. Draghiciu O, Lubbers J, Nijman HW, Daemen T. 2015. Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology 4(1):e954829.
14. Driggers PH, Ennist DL, Gleason SL, Mak WH, Marks MS, Levi BZ, Flanagan JR, Appella E, Ozato K. 1990. An interferon gamma-regulated protein that binds the interferoninducible enhancer element of major histocompatibility complex class I genes. Proc Natl Acad Sci U S A 87(10): 3743-3747.
15. Dror N, Rave-Harel N, Burchert A, Azriel A, Tamura T, Tailor P, Neubauer A, Ozato K, Levi BZ. 2007. Interferon regulatory factor-8 is indispensable for the expression of promyelocytic leukemia and the formation of nuclear bodies in myeloid cells. J Biol Chem 282(8):5633-5640.
16. Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, Bui J, Chan R, Diamond M, White JM, Sheehan KC, Schreiber RD. 2005. Interferon-gamma and cancer immunoediting. Immunol Res 32(1-3):231-245.
17. Dunn GP, Old LJ, Schreiber RD. 2004a. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137-148.
18. Dunn GP, Old LJ, Schreiber RD. 2004b. The three Es of cancer immunoediting. Annu Rev Immunol 22:329-360.
19. Esashi E, Wang YH, Perng O, Qin XF, Liu YJ, Watowich SS. 2008. The signal transducer STAT5 inhibits plasmacytoid dendritic cell development by suppressing transcription factor IRF8. Immunity 28(4):509-520.
20. Farrar MA, Schreiber RD. 1993. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 11:571-611.
21. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. 2011. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 60(10):1419-1430.
22. Gabriele L, Phung J, Fukumoto J, Segal D, Wang IM, Giannakakou P, Giese NA, Ozato K, Morse HC, 3rd. 1999. Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. J Exp Med 190(3):411-421.
23. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, Schreiber H. 2007. The terminology issue for myeloid-derived suppressor cells. Cancer Res 67(1):425; author reply 426.
24. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. 2012. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12(4):253-268.
25. Giese NA, Gabriele L, Doherty TM, Klinman DM, Tadesse- Heath L, Contursi C, Epstein SL, Morse HC, 3rd. 1997. Interferon (IFN) consensus sequence-binding protein, a transcription factor of the IFN regulatory factor family, regulates immune responses in vivo through control of interleukin 12 expression. J Exp Med 186(9):1535-1546.
26. Goh C, Narayanan S, Hahn YS. 2013. Myeloid-derived suppressor cells: the dark knight or the joker in viral infections? Immunol Rev 255(1):210-221.
27. Greeneltch KM, Schneider M, Steinberg SM, Liewehr DJ, Stewart TJ, Liu K, Abrams SI. 2007. Host immunosurveillance controls tumor growth via IFN regulatory factor-8 dependent mechanisms. Cancer Res 67(21):10406-10416.
28. Hambleton S, Salem S, Bustamante J, Bigley V, Boisson- Dupuis S, Azevedo J, Fortin A, Haniffa M, Ceron-Gutierrez L, Bacon CM, Menon G, Trouillet C, McDonald D, Carey P, Ginhoux F, Alsina L, Zumwalt TJ, Kong XF, Kumararatne D, Butler K, Hubeau M, Feinberg J, Al-Muhsen S, Cant A, Abel L, Chaussabel D, Doffinger R, Talesnik E, Grumach A, Duarte A, Abarca K, Moraes-Vasconcelos D, Burk D, Berghuis A, Geissmann F, Collin M, Casanova JL, Gros P. 2011. IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med 365(2):127-138.
29. Highfill SL, Rodriguez PC, Zhou Q, Goetz CA, Koehn BH, Veenstra R, Taylor PA, Panoskaltsis-Mortari A, Serody JS, Munn DH, Tolar J, Ochoa AC, Blazar BR. 2010. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13. Blood 116(25): 5738-5747.
30. Hirai H, Zhang P, Dayaram T, Hetherington CJ, Mizuno S, Imanishi J, Akashi K, Tenen DG. 2006. C/EBPbeta is required for 'emergency' granulopoiesis. Nat Immunol 7(7):732-739.
31. Holtschke T, Lohler J, Kanno Y, Fehr T, Giese N, Rosenbauer F, Lou J, Knobeloch KP, Gabriele L, Waring JF, Bachmann MF, Zinkernagel RM, Morse HC, 3rd, Ozato K, Horak I. 1996. Immunodeficiency and chronic myelogenous leukemialike syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87(2):307-317.
32. Hortner M, Nielsch U, Mayr LM, Johnston JA, Heinrich PC, Haan S. 2002. Suppressor of cytokine signaling-3 is recruited to the activated granulocyte-colony stimulating factor receptor and modulates its signal transduction. J Immunol 169(3):1219-1227.
33. Hu X, Bardhan K, Paschall AV, Yang D, Waller JL, Park MA, Nayak-Kapoor A, Samuel TA, Abrams SI, Liu K. 2013. Deregulation of apoptotic factors Bcl-xL and Bax confers apoptotic resistance to myeloid-derived suppressor cells and contributes to their persistence in cancer. J Biol Chem 288(26): 19103-19115.
34. Huang W, Horvath E, Eklund EA. 2007. PU.1, interferon regulatory factor (IRF) 2, and the interferon consensus sequencebinding protein (ICSBP/IRF8) cooperate to activate NF1 transcription in differentiating myeloid cells. J Biol Chem 282(9):6629-6643.
35. Huang W, Zhu C, Wang H, Horvath E, Eklund EA. 2008. The interferon consensus sequence-binding protein (ICSBP/IRF8) represses PTPN13 gene transcription in differentiating myeloid cells. J Biol Chem 283(12):7921-7935.
36. Ikeda H, Old LJ, Schreiber RD. 2002. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13(2):95-109.
37. Jin J, Wang X, Wang Q, Guo X, Cao J, Zhang X, Zhu T, Zhang D, Wang W, Wang J, Shen B, Gao X, Shi Y, Zhang J. 2013. Chronic psychological stress induces the accumulation of myeloid-derived suppressor cells in mice. PLoS One 8(9): e74497.
38. Joshita S, Nakazawa K, Sugiyama Y, Kamijo A, Matsubayashi K, Miyabayashi H, Furuta K, Kitano K, Kawa S. 2009. Granulocyte-colony stimulating factor-producing pancreatic adenosquamous carcinoma showing aggressive clinical course. Intern Med 48(9):687-691.
39. Kanno Y, Kozak CA, Schindler C, Driggers PH, Ennist DL, Gleason SL, Darnell JE, Jr., Ozato K. 1993. The genomic structure of the murine ICSBP gene reveals the presence of the gamma interferon-responsive element, to which an ISGF3 alpha subunit (or similar) molecule binds. Mol Cell Biol 13(7):3951-3963.
40. Kim YM, Kang HS, Paik SG, Pyun KH, Anderson KL, Torbett BE, Choi I. 1999. Roles of IFN consensus sequence binding protein and PU.1 in regulating IL-18 gene expression. J Immunol 163(4):2000-2007.
41. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon- Thomas S, Niu G, Kay H, Mule J, Kerr WG, Jove R, Pardoll D, Yu H. 2005. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11(12):1314-1321.
42. Kubo M, Hanada T, Yoshimura A. 2003. Suppressors of cytokine signaling and immunity. Nat Immunol 4(12):1169-1176.
43. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. 2008. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest 118(10):3367-3377.
44. Kurotaki D, Yamamoto M, Nishiyama A, Uno K, Ban T, Ichino M, Sasaki H, Matsunaga S, Yoshinari M, Ryo A, Nakazawa M, Ozato K, Tamura T. 2014. IRF8 inhibits C/EBPalpha activity to restrain mononuclear phagocyte progenitors from differentiating into neutrophils. Nat Commun 5:4978.
45. Kusmartsev S, Gabrilovich DI. 2006. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 25(3):323-331.
46. Kuwata T, Gongora C, Kanno Y, Sakaguchi K, Tamura T, Kanno T, Basrur V, Martinez R, Appella E, Golub T, Ozato K. 2002. Gamma interferon triggers interaction between ICSBP (IRF-8) and TEL, recruiting the histone deacetylase HDAC3 to the interferon-responsive element. Mol Cell Biol 22(21):7439-7448.
47. Kyo S, Kanaya T, Takakura M, Inoue M. 2000. A case of cervical cancer with aggressive tumor growth: possible autocrine growth stimulation by G-CSF and Il-6. Gynecol Oncol 78(3 Pt 1):383-387.
48. Lee CH, Melchers M, Wang H, Torrey TA, Slota R, Qi CF, Kim JY, Lugar P, Kong HJ, Farrington L, van der Zouwen B, Zhou JX, Lougaris V, Lipsky PE, Grammer AC, Morse HC, 3rd. 2006. Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequencebinding protein. J Exp Med 203(1):63-72.
49. Lee W, Kim HS, Baek SY, Lee GR. 2015. Transcription factor IRF8 controls Th1-like regulatory T-cell function. Cell Mol Immunol [Epub ahead of print]; DOI: 10.1038/cmi.2015.72.
50. Levi BZ, Hashmueli S, Gleit-Kielmanowicz M, Azriel A, Meraro D. 2002. ICSBP/IRF-8 transactivation: a tale of protein-protein interaction. J Interferon Cytokine Res 22(1): 153-160.
51. Liu J, Guan X, Tamura T, Ozato K, Ma X. 2004. Synergistic activation of interleukin-12 p35 gene transcription by interferon regulatory factor-1 and interferon consensus sequencebinding protein. J Biol Chem 279(53):55609-55617.
52. Liu J, Ma X. 2006. Interferon regulatory factor 8 regulates RANTES gene transcription in cooperation with interferon regulatory factor-1, NF-kappaB, and PU.1. J Biol Chem 281(28):19188-19195.
53. Liu K, Abrams SI. 2003. Coordinate regulation of IFN consensus sequence-binding protein and caspase-1 in the sensitization of human colon carcinoma cells to Fas-mediated apoptosis by IFN-gamma. J Immunol 170(12):6329-6337.
54. Lu R, Medina KL, Lancki DW, Singh H. 2003. IRF-4, 8 orchestrate the pre-B-to-B transition in lymphocyte development. Genes Dev 17(14):1703-1708.
55. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion- Sileni V, Mocellin S, Zanon A, Rossi CR, Nitti D, Bronte V, Zanovello P. 2009. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 182(10):6562-6568.
56. Manz MG, Boettcher S. 2014. Emergency granulopoiesis. Nat Rev Immunol 14(5):302-314.
57. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, Ugel S, Sonda N, Bicciato S, Falisi E, Calabrese F, Basso G, Zanovello P, Cozzi E, Mandruzzato S, Bronte V. 2010. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 32(6):790-802.
58. Marvel D, Gabrilovich DI. 2015. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 125(9):3356-3364.
59. Masumi A, Tamaoki S, Wang IM, Ozato K, Komuro K. 2002. IRF-8/ICSBP and IRF-1 cooperatively stimulate mouse IL-12 promoter activity in macrophages. FEBS Lett 531(2):348-353.
60. Messmer MN, Netherby CS, Banik D, Abrams SI. 2015. Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy. Cancer Immunol Immunother 64(1): 1-13.
61. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA. 2008. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111(8):4233-4244.
62. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H. 1999. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci U S A 96(15):8633-8638.
63. Nefedova Y, Huang M, Kusmartsev S, Bhattacharya R, Cheng P, Salup R, Jove R, Gabrilovich D. 2004. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol 172(1):464-474.
64. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. 2005. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 65(20):9525-9535.
65. Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio MR, Ebert BL, Griffin JD, Frank DA. 2011. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 117(12):3421-3429.
66. Nelson N, Marks MS, Driggers PH, Ozato K. 1993. Interferon consensus sequence-binding protein, a member of the interferon regulatory factor family, suppresses interferon-induced gene transcription. Mol Cell Biol 13(1):588-599.
67. Ostrand-Rosenberg S. 2010. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59(10):1593-1600.
68. Ostrand-Rosenberg S, Sinha P. 2009. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182(8):4499-4506.
69. Ostrand-Rosenberg S, Sinha P, Beury DW, Clements VK. 2012. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 22(4):275-281.
70. Ouyang X, Zhang R, Yang J, Li Q, Qin L, Zhu C, Liu J, Ning H, Shin MS, Gupta M, Qi CF, He JC, Lira SA, Morse HC, 3rd, Ozato K, Mayer L, Xiong H. 2011. Transcription factor IRF8 directs a silencing programme for TH17 cell differentiation. Nat Commun 2:314.
71. Panopoulos AD, Watowich SS. 2008. Granulocyte colonystimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis. Cytokine 42(3): 277-288.
72. Papaspyridonos M, Matei I, Huang Y, do Rosario Andre M, Brazier-Mitouart H, Waite JC, Chan AS, Kalter J, Ramos I, Wu Q, Williams C, Wolchok JD, Chapman PB, Peinado H, Anandasabapathy N, Ocean AJ, Kaplan RN, Greenfield JP, Bromberg J, Skokos D, Lyden D. 2015. Id1 suppresses antitumour immune responses and promotes tumour progression by impairing myeloid cell maturation. Nat Commun 6:6840.
73. Paschall AV, Zhang R, Qi CF, Bardhan K, Peng L, Lu G, Yang J, Merad M, McGaha T, Zhou G, Mellor A, Abrams SI, Morse HC, 3rd, Ozato K, Xiong H, Liu K. 2015. IFN regulatory factor 8 represses GM-CSF expression in T cells to affect myeloid cell lineage differentiation. J Immunol 194(5): 2369-2379.
74. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. 2010. Immature immunosuppressive CD14+HLA-DR-/ low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 70(11):4335-4345.
75. Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT, Tenen DG. 1998. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 18(7):4301-4314.
76. Ray A, Chakraborty K, Ray P. 2013. Immunosuppressive MDSCs induced by TLR signaling during infection and role in resolution of inflammation. Front Cell Infect Microbiol 3:52.
77. Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, Garcia J, Vogelbaum MA, Finke J. 2011. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 13(6):591-599.
78. Rebe C, Vegran F, Berger H, Ghiringhelli F. 2013. STAT3 activation: a key factor in tumor immunoescape. JAKSTAT 2(1):e23010.
79. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC. 2009. Arginase I-producing myeloidderived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 69(4):1553-1560.
80. Savarese TM, Mitchell K, McQuain C, Campbell CL, Guardiani R, Wuu J, Ollari C, Reale F, Nelson BE, Chen A, Quesenberry PJ. 2001. Coexpression of granulocyte colony stimulating factor and its receptor in primary ovarian carcinomas. Cancer Lett 162(1):105-115.
81. Scheller M, Foerster J, Heyworth CM, Waring JF, Lohler J, Gilmore GL, Shadduck RK, Dexter TM, Horak I. 1999. Altered development and cytokine responses of myeloid progenitors in the absence of transcription factor, interferon consensus sequence binding protein. Blood 94(11):3764-3771.
82. Schiavoni G, Mattei F, Borghi P, Sestili P, Venditti M, Morse HC, 3rd, Belardelli F, Gabriele L. 2004. ICSBP is critically involved in the normal development and trafficking of Langerhans cells and dermal dendritic cells. Blood 103(6):2221-2228.
83. Schmidt M, Bies J, Tamura T, Ozato K, Wolff L. 2004. The interferon regulatory factor ICSBP/IRF-8 in combination with PU.1 up-regulates expression of tumor suppressor p15(Ink4b) in murine myeloid cells. Blood 103(11):4142-4149.
84. Schmidt M, Hochhaus A, Nitsche A, Hehlmann R, Neubauer A. 2001. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha. Blood 97(11):3648-3650.
85. Schmidt M, Nagel S, Proba J, Thiede C, Ritter M, Waring JF, Rosenbauer F, Huhn D, Wittig B, Horak I, Neubauer A. 1998. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 91(1):22-29.
86. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. 2001. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410(6832):1107-1111.
87. Sharf R, Meraro D, Azriel A, Thornton AM, Ozato K, Petricoin EF, Larner AC, Schaper F, Hauser H, Levi BZ. 1997. Phosphorylation events modulate the ability of interferon consensus sequence binding protein to interact with interferon regulatory factors and to bind DNA. J Biol Chem 272(15):9785-9792.
88. Smith MA, Wright G, Wu J, Tailor P, Ozato K, Chen X, Wei S, Piskurich JF, Ting JP, Wright KL. 2011. Positive regulatory domain I (PRDM1) and IRF8/PU.1 counter-regulate MHC class II transactivator (CIITA) expression during dendritic cell maturation. J Biol Chem 286(10):7893-7904.
89. Sonda N, Chioda M, Zilio S, Simonato F, Bronte V. 2011. Transcription factors in myeloid-derived suppressor cell recruitment and function. Curr Opin Immunol 23(2):279-285.
90. Talmadge JE, Gabrilovich DI. 2013. History of myeloid-derived suppressor cells. Nat Rev Cancer 13(10):739-752.
91. Tamura T, Kurotaki D, Koizumi S. 2015. Regulation of myelopoiesis by the transcription factor IRF8. Int J Hematol 101(4):342-351.
92. Tamura T, Nagamura-Inoue T, Shmeltzer Z, Kuwata T, Ozato K. 2000. ICSBP directs bipotential myeloid progenitor cells to differentiate into mature macrophages. Immunity 13(2): 155-165.
93. Tamura T, Ozato K. 2002. ICSBP/IRF-8: its regulatory roles in the development of myeloid cells. J Interferon Cytokine Res 22(1):145-152.
94. Tamura T, Tailor P, Yamaoka K, Kong HJ, Tsujimura H, O'Shea JJ, Singh H, Ozato K. 2005a. IFN regulatory factor-4 and -8 govern dendritic cell subset development and their functional diversity. J Immunol 174(5):2573-2581.
95. Tamura T, Thotakura P, Tanaka TS, Ko MS, Ozato K. 2005b. Identification of target genes and a unique cis element regulated by IRF-8 in developing macrophages. Blood 106(6):1938-1947.
96. Tamura T, Yanai H, Savitsky D, Taniguchi T. 2008. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 26:535-584.
97. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. 2001. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 19:623-655.
98. Tian SS, Lamb P, Seidel HM, Stein RB, Rosen J. 1994. Rapid activation of the STAT3 transcription factor by granulocyte colony-stimulating factor. Blood 84(6):1760-1764.
99. Tsujimura H, Nagamura-Inoue T, Tamura T, Ozato K. 2002. IFN consensus sequence binding protein/IFN regulatory factor-8 guides bone marrow progenitor cells toward the macrophage lineage. J Immunol 169(3):1261-1269.
100. Tsukuda M, Nagahara T, Yago T, Matsuda H, Yanoma S. 1993. Production of granulocyte colony-stimulating factor by head and neck carcinomas. Biotherapy 6(3):183-187.
101. Tu SP, Jin H, Shi JD, Zhu LM, Suo Y, Lu G, Liu A, Wang TC, Yang CS. 2012. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res (Phila) 5(2):205-215.
102. Turcotte K, Gauthier S, Mitsos LM, Shustik C, Copeland NG, Jenkins NA, Fournet JC, Jolicoeur P, Gros P. 2004. Genetic control of myeloproliferation in BXH-2 mice. Blood 103(6): 2343-2350.
103. Turcotte K, Gauthier S, Tuite A, Mullick A, Malo D, Gros P. 2005. A mutation in the Icsbp1 gene causes susceptibility to infection and a chronic myeloid leukemia-like syndrome in BXH-2 mice. J Exp Med 201(6):881-890.
104. Ugel S, De Sanctis F, Mandruzzato S, Bronte V. 2015. Tumorinduced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest 125(9):3365-3376.
105. Vidovic K, Svensson E, Nilsson B, Thuresson B, Olofsson T, Lennartsson A, Gullberg U. 2010. Wilms' tumor gene 1 protein represses the expression of the tumor suppressor interferon regulatory factor 8 in human hematopoietic progenitors and in leukemic cells. Leukemia 24(5):992-1000.
106. Waight JD, Banik D, Griffiths EA, Nemeth MJ, Abrams SI. 2014. Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia. J Biol Chem 289(22):15642-15652.
107. Waight JD, Hu Q, Miller A, Liu S, Abrams SI. 2011. Tumorderived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One 6(11):e27690.
108. Waight JD, Netherby C, Hensen ML, Miller A, Hu Q, Liu S, Bogner PN, Farren MR, Lee KP, Liu K, Abrams SI. 2013. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest 123(10):4464-4478.
109. Wang H, Yan M, Sun J, Jain S, Yoshimi R, Abolfath SM, Ozato K, Coleman WG, Jr., Ng AP, Metcalf D, DiRago L, Nutt SL, Morse HC, 3rd. 2014. A reporter mouse reveals lineage-specific and heterogeneous expression of IRF8 during lymphoid and myeloid cell differentiation. J Immunol 193(4):1766-1777.
110. Wang IM, Contursi C, Masumi A, Ma X, Trinchieri G, Ozato K. 2000. An IFN-gamma-inducible transcription factor, IFN consensus sequence binding protein (ICSBP), stimulates IL-12 p40 expression in macrophages. J Immunol 165(1):271-279.
111. Watanabe T, Hotta C, Koizumi S, Miyashita K, Nakabayashi J, Kurotaki D, Sato GR, Yamamoto M, Nakazawa M, Fujita H, Sakai R, Fujisawa S, Nishiyama A, Ikezawa Z, Aihara M, Ishigatsubo Y, Tamura T. 2013. The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia. Cancer Res 73(22):6642-6653.
112. Wu WC, Sun HW, Chen HT, Liang J, Yu XJ, Wu C, Wang Z, Zheng L. 2014. Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients. Proc Natl Acad Sci U S A 111(11):4221-4226.
113. Xin H, Zhang C, Herrmann A, Du Y, Figlin R, Yu H. 2009. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res 69(6):2506-2513.
114. Yanez A, Ng MY, Hassanzadeh-Kiabi N, Goodridge HS. 2015. IRF8 acts in lineage-committed rather than oligopotent progenitors to control neutrophil vs monocyte production. Blood 125(9):1452-1459.
115. Yang D, Wang S, Brooks C, Dong Z, Schoenlein PV, Kumar V, Ouyang X, Xiong H, Lahat G, Hayes-Jordan A, Lazar A, Pollock R, Lev D, Liu K. 2009. IFN regulatory factor 8 sensitizes soft tissue sarcoma cells to death receptor-initiated apoptosis via repression of FLICE-like protein expression. Cancer Res 69(3):1080-1088.
116. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI. 2008. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181(8):5791-5802.
117. Yu H, Liu Y, McFarland BC, Deshane JS, Hurst DR, Ponnazhagan S, Benveniste EN, Qin H. 2015. SOCS3 deficiency in myeloid cells promotes tumor development: involvement of STAT3 activation and myeloid-derived suppressor cells. Cancer Immunol Res 3(7):727-740.
118. Yu J, Du W, Yan F, Wang Y, Li H, Cao S, Yu W, Shen C, Liu J, Ren X. 2013. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 190(7):3783-3797.
119. Zaidi MR, Merlino G. 2011. The two faces of interferon-gamma in cancer. Clin Cancer Res 17(19):6118-6124.
120. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. 1997. Absence of granulocyte colonystimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci U S A 94(2):569-574.
121. Zhang H, Nguyen-Jackson H, Panopoulos AD, Li HS, Murray PJ, Watowich SS. 2010. STAT3 controls myeloid progenitor growth during emergency granulopoiesis. Blood 116(14): 2462-2471.